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Activated protein C (APC) has endothelial 
barrier protective effects that require binding 
to endothelial protein C receptor (EPCR) and 
cleavage of protease activated receptor-1 
(PAR1) and that may play a role in the anti-
inflammatory action of APC. In this study we 
investigated whether protein C (PC) 
activation by thrombin on the endothelial cell 
surface may be linked to efficient protective 
signaling. To minimize direct thrombin effects 
on endothelial permeability we used the 
anticoagulant double mutant thrombin 
W215A/E217A (WE). Activation of PC by 
WE on the endothelial cell surface generated 
APC with high barrier protective activity. 
Comparable barrier protective effects by 
exogenous APC required a four fold higher 
concentration of APC. To demonstrate 
conclusively that protective effects in the 
presence of WE are mediated by APC 
generation and not direct signaling by WE, we 
used a PC variant with a substitution of the 
active site serine with alanine (PC S360A). 
Barrier protective effects of a low 
concentration of exogenous APC were 
blocked by both wildtype PC and PC S360A, 
consistent with their expected role as 
competitive inhibitors for APC binding to 
EPCR. WE induced protective signaling only 
in the presence of wildtype PC but not PC 
S360A and PAR1 cleavage was required for 
these protective effects. These data 
demonstrate that the endogenous PC 
activation pathway on the endothelial cell 
surface is mechanistically linked to PAR1-
dependent autocrine barrier protective 
signaling by the generated APC. WE may 
have powerful protective effects in systemic 
inflammation through signaling by the 
endogenously generated APC. 
Thrombin plays a key role in the blood 
coagulation system because it not only activates 
platelets and clots fibrinogen, but also initiates 
the anticoagulant protein C (PC)1 pathway. 
When thrombin binds to its receptor 
thrombomodulin on the surface of endothelial 
cells it loses its procoagulant functions and 
generates activated PC (APC) (1,2). Endothelial 
PC receptor (EPCR) binds both PC and APC and 
activation of EPCR-bound PC by the thrombin-
thrombomodulin complex is enhanced (3). The 
generated APC in turn degrades cofactors Va and 
VIIIa that are required for efficient prothrombin 
activation, providing critical negative feedback 
regulation of thrombin generation. Intravenous 
infusion of recombinant APC reduces mortality 
in patients with severe sepsis (4) and current 
evidence indicates that APC has protective 
effects in systemic inflammation that are at least 
in part independent from its role as an 
anticoagulant. 
A number of studies have indicated that 
exogenous APC can regulate cellular functions 
of endothelial cells, including gene expression 
(5-8), survival (9,10), proliferation (11), and 
barrier permeability (12-14). It is likely that 
many, if not all of these effects, require binding 
of APC to EPCR and activation of protease-
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activated receptors (PARs) on the endothelial 
surface. Specifically activation of the thrombin 
receptor PAR1 is required for APC signaling in 
endothelial cells (7-10,13) and the EPCR-APC-
PAR1 signaling cascade has been implicated in 
mediating neuroprotective effects of APC in vivo 
(9,15).  
Compared to thrombin, APC is a very 
inefficient PAR1 activator and recent studies 
indicate that some PAR1 dependent responses of 
endothelial cells such as gene induction and 
barrier disruption require ~104-fold higher 
concentrations of APC than thrombin (13,16). 
On the other hand, our previous results 
demonstrate that low concentrations of APC (~1 
nM) have powerful PAR1-dependent endothelial 
barrier protective effects that can be 
recapitulated by incubation with very low (~40 
pM) but not higher concentrations of thrombin 
(13), raising the possibility that APC-PAR1 
signaling may protect in systemic inflammation 
precisely because APC is a relatively inefficient 
PAR1 activator. Whereas intravenous infusion of 
APC has protective effects that are not entirely 
explained by its anticoagulant function, it is 
currently unknown whether the endogenously 
generated APC has an anti-inflammatory or other 
protective role in addition to its well established 
function as an antithrombotic agent. How can 
activation of the prototypical thrombin receptor 
PAR1 on endothelial cells by endogenously 
generated APC be relevant if the generation of 
APC is thrombin dependent and thrombin is a 
much more efficient PAR1 activator? Compared 
to APC the half-life of thrombin in the 
circulation is very short (17) and one possibility 
is that APC acts on endothelial cells that are not 
exposed to thrombin and are thus not involved in 
the activation of PC. However, the APC 
concentration in normal plasma is only 20-40 
pM (18,19) and this APC would have to compete 
for EPCR binding with PC which circulates in 
plasma at ~80 nM (20,21) in order to induce 
endothelial cell signaling. Although at sites in 
close proximity to ongoing clotting higher local 
APC concentrations may be achieved while PC 
is depleted, an intriguing other possibility is that 
autocrine APC signaling is directly coupled to 
the process of zymogen activation, especially 
given that EPCR binding supports both PC 
activation and APC signaling. Accordingly, we 
set out in the present study to determine whether 
protective signaling by endogenously generated 
APC is enhanced compared with exogenous 
APC. We used a thrombin variant with higher 
relative specificity for PC activation to 
demonstrate that the endogenous PC activation 
pathway is indeed linked to efficient PAR1-
dependent barrier protective signaling, indicating 
that the generated APC can be directly channeled 
into the protective signaling pathway. 
MATERIALS AND METHODS 
Agonists, inhibitors, and antibodies - 
Human thrombin and the specific agonist peptide 
for PAR2 (SLIGRL) were as described (7,22,23) 
and human plasma derived PC, APC, and factor 
Xa were from Haematologic Technologies 
(Essex Junction, VT). Mutant recombinant 
human thrombin W215A/E217A (WE) was 
provided by Dr. Di Cera (24) and the active site 
concentrations of both wildtype thrombin and 
WE were determined by titration with hirudin 
using S-2238 (diaPharma, West Chester, OH) as 
the amidolytic substrate. Recombinant human 
wildtype PC and PC S360A were expressed, 
activated, purified, and characterized as 
described previously (25). The PC preparations 
were free of detectable APC (<0.1%) and 
thrombin (<0.04 pM in 100 nM PC) as 
determined by amidolytic assays. PAR1 
cleavage-blocking monoclonal antibodies 
ATAP2 and WEDE15 have been characterized 
previously and were used in combination at 10 
µg/ml and 25 µg/ml, respectively (7,22,26). The 
activity-blocking C1 anti-PC monoclonal 
antibody was as described (21). Hirudin was 
from Calbiochem (La Jolla, CA) and 
recombinant nematode anticoagulant protein 5 
(NAP5) (27) was kindly provided by Dr. George 
Vlasuk (Corvas International, San Diego, CA).  
Cell culture - The transformed human 
endothelial cell line EA.hy926 (28) was provided 
by Dr. Cora Edgell (University of North Carolina 
at Chapel Hill, NC). Cells were grown to 
confluency in a humidified atmosphere at 37°C 
in Dulbecco’s Modified Eagle Medium 
(Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum (Omega Scientific, 
Tarzana, CA). Human aortic endothelial cells 
(HAECs) were obtained from Clonetics 
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(Walkersville, MD) and grown according to the 
manufacturer’s recommendations. 
APC activity assay - APC activity was 
measured by adding 50 µl conditioned medium 
to 100 µl of HEPES-buffered saline containing 
100 nM hirudin in order to block thrombin. 50 µl 
of the APC substrate S-2366 (diaPharma) or 
Spectrozyme PCa (#336; American Diagnostica, 
Stamford, CT) was added to obtain a final 
substrate concentration of 0.25 mM and the rate 
of substrate hydrolysis was determined by 
analyzing the change in absorbance at 405 nm 
over time (mOD/min) at room temperature using 
a Vmax kinetic microplate reader (Molecular 
Devices, Menlo Park, CA). Xa activity was 
determined in control experiments using 
Spectrozyme Xa (American Diagnostica). 
Permeability assay - Macromolecular 
monolayer permeability was analyzed in a dual 
chamber system using Evans blue-labeled bovine 
serum albumin (BSA) as described previously 
(13,23). Briefly, EA.hy926 cells were plated on 
Transwell polycarbonate membranes of 3-µm 
pore size and 12-mm diameter (Costar, Corning, 
NY). The upper and lower chambers were filled 
with 500 µl and 1500 µl growth medium, 
respectively. Cells were grown for 2 days to 
obtain a monolayer with less well established 
cell-cell contacts (“subconfluent cells”) or for 3-
4 days to obtain a tight monolayer (“confluent 
cells”). Agonists were added in serum-free 
medium containing 0.4% BSA (Calbiochem) and 
permeability was assayed 3 h later using 0.67 
mg/ml Evans blue (Sigma, St. Louis, MO) 
diluted in growth medium containing 4% BSA. 
Fresh growth medium was added to the lower 
chamber and the medium in the upper chamber 
was replaced with Evans blue/BSA. After 10 
minutes the optical density at 650 nm was 
measured in a 1:3 diluted 50 µl sample from the 
lower chamber. For thrombin treatment of the 
monolayers, medium was removed and 5 nM 
thrombin was added for 10 min in serum free 
medium followed by analysis of permeability.  
Analysis of MAP kinase activation - 
Mitogen-activated protein (MAP) kinase 
phosphorylation was analyzed by Western 
blotting of whole cell lysates using an anti-
phospho-extracellular signal-regulated kinase-
1/2 (Erk1/2) antibody (#9101; Cell Signaling 
Technology, Beverly, MA) in an enhanced 
chemiluminescence-based detection system as 
described (7,13). Staining with anti-actin 
(Sigma) served as loading control.  
Statistical analysis - A two-tailed t-test 
was used to calculate the indicated p-values. 
RESULTS 
APC generation on the endothelial cell 
surface - When EA.hy926 endothelial cells were 
incubated in the presence of 80 nM purified 
human PC and different concentrations of 
thrombin a dose-dependent linear increase in 
amidolytic activity towards a chromogenic APC 
substrate was observed over time in the culture 
medium (Fig. 1A). The amidolytic activity was 
identified as APC using the activity blocking 
monoclonal anti-PC antibody C1 (21). C1 
reduced the activity of purified APC as well as 
the generated amidolytic activity to 10-15% of 
control without C1 whereas the amidolytic 
activity of factor Xa was not affected by C1 
(results not shown). No detectable amidolytic 
activity was generated in the absence of either 
PC or cells (not shown), demonstrating cell 
surface-dependent APC generation in our assay. 
The activity of 10 nM exogenously added APC 
decreased only slightly under the conditions of 
the assay (92% of the initial amidolytic activity 
of 34 mOD/min after 3 h). Some APC generation 
was consistently observed in the absence of 
exogenous thrombin, even when the cell layer 
had been extensively washed. The rate of this 
APC generation increased over time and it was 
blocked by both hirudin and the factor Xa 
inhibitor NAP5 (Fig. 1A). Inhibition of factor Xa 
with NAP5 did not affect PC activation by 
exogenously added thrombin in this assay (not 
shown) and all subsequent experiments were 
performed in the presence of 1 µM NAP5 to 
allow a strict control of the thrombin 
concentration in the system.  
Barrier protective effects in response to 
low-dose thrombin in the presence and absence 
of PC - We have previously shown in a dual 
chamber system measuring albumin flux that 
incubation with very low concentrations of 
thrombin (~40 pM) can increase barrier integrity 
of a subconfluent layer of endothelial cells and 
can protect a confluent monolayer from barrier 
disruption by a higher dose of thrombin. This 
protective effect was not mediated by receptor 
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desensitization (13). In order to test whether 
endogenously generated APC can support barrier 
protection in response to even lower 
concentrations of thrombin, we incubated 
confluent cells with 10-40 pM thrombin in the 
absence and presence of PC. Consistent with our 
previous results, 40 pM thrombin was barrier 
protective, whereas a significant protective effect 
in response to 20 pM thrombin was found only 
in the presence of PC (Fig. 1B). Although these 
results are consistent with the hypothesis that 
barrier protective effects of low-dose thrombin 
and generated APC are additive, they also 
indicate that it will be difficult to compare 
protective effects of exogenous and 
endogenously generated APC in this system 
because the thrombin concentrations required to 
support APC generation are similar to the 
concentrations that lead to direct barrier 
protective effects. 
WE supports PC activation at 
concentrations that do not induce direct 
signaling - The double mutant thrombin 
W215A/E217A (WE) has a higher relative 
specificity for thrombomodulin-dependent PC 
activation than for PAR1 activation compared to 
the wildtype in a purified system using human 
PC/rabbit thrombomodulin and a soluble PAR1 
fragment corresponding to the extracellular 
portion of the receptor (24). Because relative 
specificities on the cell surface in the presence of 
cofactors could be different, PC activation and 
PAR1 dependent signaling were analyzed on the 
endothelial cells. In this system, WE was almost 
100-fold less active than wildtype thrombin for 
PC activation (Fig. 2A). However, the PAR1-
dependent induction of MAP kinase 
phosphorylation required more than 1000-fold 
higher concentrations of the thrombin mutant 
(Fig. 2B). Thus, 2-10 nM WE lead to significant 
APC generation without directly inducing 
PAR1-dependent signaling. As shown in Fig. 
2C, incubation in the presence of up to 16 nM 
WE did indeed not lead to barrier protective 
effects in the dual chamber system. These results 
suggest that the mutant thrombin may allow the 
analysis of protective signaling by endogenously 
generated APC in the absence of direct thrombin 
signaling. 
Efficient barrier protective signaling in 
response to WE in the presence of PC - Cells 
were incubated with a series of different 
concentrations of either WE in the presence of 
80 nM PC or exogenous APC. After 3 h, the 
APC concentration in the cell medium and 
barrier integrity of the monolayer were measured 
(Fig. 3). The lowest concentration of WE that 
induced a significant barrier protective response 
in the presence of PC was 2 nM and 1.3 nM APC 
were generated under these conditions (Fig. 3D). 
For a similarly effective response 5 nM 
exogenous APC were required. Thus, based upon 
the amount of APC present after the 3 h 
incubation, protective signaling by WE in the 
presence of PC is about four times more efficient 
compared to exogenous APC. Importantly, APC 
is generated from PC at a constant rate during the 
incubation period while exogenous APC loses 
some activity. Therefore, the differential between 
exogenous and endogenously generated APC is 
at least eight-fold when the average APC 
concentrations during incubation are compared. 
We used human aortic endothelial cells (HAECs) 
in order to confirm that these results are not a 
specific property of the endothelial EA.hy926 
cell line. These cells formed a tight and 
thrombin-responsive monolayer in our dual 
chamber system and exogenous APC was barrier 
protective at concentrations of 2 nM and higher. 
HAECs supported PC activation at a somewhat 
lower rate (~20%) compared to EA.hy926 cells, 
presumably because thrombomodulin expression 
is lower. Barrier protective signaling in response 
to 2 nM exogenous APC and 2 nM WE in the 
presence of 80 nM PC was comparably effective 
(Fig. 4). WE in the absence of PC had no effect. 
Only 0.2 nM APC were generated on HAECs 
during the 3 h incubation with 2 nM WE/80 nM 
PC. Thus, the results are consistent with those 
shown in Fig. 3 and they demonstrate that 
enhanced signaling by endogenously generated 
APC is not an anomalous property specific for 
the EA.hy926 cell line. Taken together, these 
data suggest that the endogenous PC activation 
pathway is indeed linked to efficient protective 
signaling. However, additional control 
experiments are required to rule out two 
alternative explanations that involve direct 
signaling by WE in the presence of PC: (i) Direct 
protective signaling by WE may be enhanced in 
the presence of the substrate PC independent 
from APC generation and (ii) sub-threshold 
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direct signaling by WE may potentiate signaling 
by APC. 
Barrier enhancement by APC is 
mechanistically coupled to the endogenous PC 
activation pathway - Recombinant wildtype PC 
and a PC variant with a substitution of the active 
site serine with alanine (PC S360A) were used to 
address these possibilities. Control experiments 
demonstrated that after activation of the 
zymogens, recombinant wildtype APC was 
similarly effective as plasma APC in our 
permeability system and, as expected, the 
proteolytically inactive APC S360A was 
ineffective (Fig. 5). Cells were incubated without 
PC (control), with wildtype PC, or with PC 
S360A, in the presence or absence of WE (4 nM) 
and exogenous APC as indicated in Fig. 6. A low 
concentration of exogenous APC (3.3 nM) was 
used and barrier protective effects of exogenous 
APC were blocked by both wildtype PC and PC 
S360A, consistent with the expected role of 
zymogen PC as a competitive inhibitor for APC 
binding to EPCR. Incubation with exogenous 
APC in the presence of PC S360A actually led to 
a slight increase of permeability that barely 
reached statistical significance. WE induced 
protective signaling only in the presence of 
wildtype PC but not PC S360A, demonstrating 
that WE does not lead to barrier enhancement in 
the presence of the substrate PC unless 
proteolytically active APC can be generated. 
Finally, there was no protective effect by the 
combination of 3.3 nM exogenous APC and WE 
in the presence of PC S360A. Incubation with 
WE in the presence of wildtype PC led to the 
generation of only 0.9 nM APC and the barrier 
protective effects were therefore not mediated by 
additive direct effects of WE and APC. Taken 
together, these data conclusively demonstrate 
that efficient barrier enhancement by APC is 
indeed mechanistically coupled to the 
endogenous PC activation pathway.  
PAR1 cleavage is required for barrier 
protective signaling by endogenously generated 
APC - Preincubation with cleavage blocking 
antibodies against PAR1 had no effect on APC 
generation but blocked barrier protective effects 
of the endogenously generated APC (Fig. 7). 
Hyperpermeability in response to the PAR1 
agonist peptide was analyzed in these 
experiments because in contrast to thrombin the 
cleavage independent PAR1 agonist peptide can 
disrupt barrier integrity in the presence of the 
blocking antibodies (13). Thus, barrier protective 
responses not only to exogenous APC but also to 
endogenously generated APC are dependent on 
cleavage of PAR1. 
DISCUSSION 
Using a thrombin variant with a relative 
specificity that favors PC activation we 
demonstrate that the endogenous PC activation 
pathway on the endothelial cell surface is linked 
to PAR1 cleavage dependent autocrine barrier 
protective signaling by the generated APC. 
When APC is generated endogenously, the 
concentration of solution phase APC close to the 
endothelial cell surface carrying the thrombin-
thrombomodulin complex is expected to be 
higher than the average concentration measured 
in the cell medium. Is it possible that the 
elevated local concentration is the reason why 
signaling by endogenously generated APC is 
enhanced? Barrier protection was obtained in our 
system when 1.3 nM APC were generated during 
the 3 h incubation (Fig. 3). The volume in the 
upper chamber is 500 µl and thus 3.9 x 1011 
molecules APC were generated. About 50,000 
cells constitute the cell layer on the transwell 
membrane (1 cm2). Because the rate of APC 
generation is constant over time (Fig. 1) it can be 
calculated from these numbers that one cell 
generates APC in our system at a rate of about 
700 molecules/second. Francis and Palsson have 
developed mathematical models of diffusion for 
protein molecules secreted from cells and the 
maximal local concentration of solution phase 
APC directly above the cell surface at this rate of 
generation can be estimated to be on the order of 
only 0.1-0.5 nM higher than the average 
concentration in the supernatant (29), still much 
lower than the concentration of exogenous APC 
(5 nM) that was required for a similarly efficient 
protective response. In addition, solution phase 
APC generated endogenously would have to 
compete with 80 nM zymogen PC for EPCR 
binding in order to induce signaling. Therefore, 
our results cannot be explained by effects of the 
local concentration and we conclude that 
protective signaling by APC is mechanistically 
linked to PC activation.  
 5
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The Kd for the interaction of both PC 
and APC with EPCR is about 30 nM (30,31). 
Thus, at the PC plasma concentration of ~80 nM 
a large fraction of the endothelial cell surface 
EPCR is expected to be PC-bound. EPCR-PC is 
activated by thrombomodulin-thrombin and our 
data indicate that the generated APC can activate 
PAR1 while still bound to EPCR. Thus, at least 
part of the endogenously generated APC can be 
directly channeled into the PAR1-dependent 
signaling pathway. Previous data demonstrating 
that PAR1 signaling by EPCR-bound exogenous 
APC is rapidly induced (32) and that the half-life 
of EPCR-bound PC as analyzed by surface 
plasmon resonance is approximately nine 
seconds (33) are consistent with this conclusion. 
Could it be that the PC pathway and not 
thrombin may emerge as the relevant activator of 
endothelial cell PAR1 in response to low 
thrombin concentrations? Thrombin activity in 
vivo is rigorously controlled to prevent excessive 
platelet activation/fibrin formation. It is difficult 
to estimate thrombin concentrations that may be 
present at the endothelial cell surface in vivo, but 
a series of studies in PAR-deficient mice 
suggests that thrombin is generated during 
hemostasis and thrombosis at concentrations just 
above threshold levels for PAR activation: In 
mouse platelets PAR4 cleavage is required for 
thrombin signaling and PAR3 acts as a non-
signaling cofactor that recruits thrombin and 
decreases the concentration required for half 
maximal signaling between 6- and 15-fold (34). 
However, PAR3- and PAR4-deficient mice 
showed similar degrees of bleeding time 
prolongation and protection in thrombosis 
models, indicating that an about 10-fold decrease 
in platelet responsiveness to thrombin has the 
same effect as complete unresponsiveness 
(35,36). In our in vitro experiments the lowest 
concentrations of wildtype thrombin that 
supported detectable PC activation and direct 
PAR1-dependent signaling were similar (~20 
pM). However, it is possible that in vivo low 
concentrations of thrombin preferentially lead to 
PC activation and PAR1-dependent protective 
signaling by the endogenously generated APC. 
Thrombin binding to thrombomodulin blocks 
thrombin’s PAR1-interactive exosite I and blood 
flow could affect the relative efficiency of 
thrombin for thrombomodulin binding versus 
PAR1 cleavage. In addition, thrombin inhibitors 
and substrates, foremost fibrinogen, that occupy 
exosite I of thrombin are present in plasma at a 
high concentration and may shift thrombin 
responses from PAR1 towards PC pathway 
activation. Na+ binding to thrombin is required 
for efficient cleavage of PAR1 whereas PC 
activation by thrombin proceeds relatively 
normal in the presence of low Na+ concentrations 
(37). The Na+ concentration close to thrombus 
formation may be relatively low (38), again 
potentially favoring PC relative to PAR1 
activation by thrombin in the endothelial 
microenvironment. The concept that thrombin 
may be able to initiate protective PC pathway 
signaling without activating PARs is also 
supported by in vivo evidence. Infusion of a low 
concentration of wildtype thrombin leads to 
activation of the PC pathway and blocks the 
lethal inflammatory response to endotoxin in 
animal models without eliciting platelet 
activation, a highly sensitive PAR-dependent 
response (39,40).  
In a recent study, no difference in PAR1 
cleavage was observed in response to a range of 
thrombin concentrations in the presence and 
absence of PC, indicating that locally generated 
APC did not contribute to PAR1 cleavage 
beyond that effected by thrombin (16). In these 
experiments cleavage of an overexpressed tagged 
PAR1 construct in transiently transfected 
endothelial cells was analyzed. It is possible that 
compared to the endogenous receptor the 
overexpressed PAR1 is less susceptible to 
cleavage by EPCR-APC. PAR1 cleavage by 
APC is restricted by the coreceptor requirement 
for EPCR whereas thrombin is expected to 
directly bind and cleave the overexpressed 
PAR1, even on cells with a very high level of the 
overexpressed receptor. In addition, in this study 
fairly high thrombin concentrations (>100 pM) 
were required to generate detectable conversion 
of PC to APC, suggesting that thrombomodulin 
and/or EPCR expression might have been 
relatively low, again favoring PAR1 cleavage by 
thrombin compared to APC. 
Our findings raise the possibility that 
through endogenous APC generation the 
infusion of WE may induce more powerful 
protective effects in patients with sepsis than 
exogenous APC. Previous data from a baboon 
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model indicate that WE infusion can be 
antithrombotic without detectable prothrombotic 
activity or bleeding complications (41), 
suggesting that WE can be safely administered in 
vivo. Protective signaling in response to WE 
would be expected to depend on an intact 
capacity to activate PC on endothelial cells. 
Immunohistochemical studies have demonstrated 
that both thrombomodulin and EPCR expression 
on endothelial cells in purpuric skin lesions is 
reduced in children with meningococcal sepsis 
(42). Expression levels were variable and 
compared to thrombomodulin the loss of EPCR 
was on average less pronounced, suggesting that 
even endothelial cells with a strongly 
downregulated ability to endogenously activate 
PC may still respond to the EPCR-dependent 
protective signaling by exogenous APC. 
Consistent with these results, Liaw et al. have 
recently shown that the PC level and the ability 
to generate APC vary widely and independently 
in adult patients with severe sepsis (43). Therapy 
in patients with sepsis could be tailored to 
different subgroups based upon the PC level in 
plasma and the capacity for PC activation as 
follows: (i) Patients with a relatively normal 
capacity to activate PC might benefit from WE 
infusion to trigger powerful barrier protective 
effects through the endogenous PC activation 
pathway. Zymogen PC could be substituted in 
the subgroup of patients with low PC levels. (ii) 
On the other hand, patients with more severe 
disease and lower PC activation capacity may be 
more likely to respond to exogenous APC. 
Clinical studies suggest that only patients with 
severe sepsis and a high but not low risk of death 
respond favorably to therapy with exogenous 
APC (4,44). At least part of the reason for this 
finding may be that patients with a high risk of 
death are also expected to have on average lower 
levels of circulating PC and less competition for 
EPCR binding. A higher dose of APC may be 
required for protective effects in patients with 
relatively high PC levels and infusion of a 
variant APC with reduced anticoagulant but 
normal anti-inflammatory activity (25) may help 
prevent hemorrhagic complications in these 
patients. In addition, especially in this group of 
patients a variant of APC with increased affinity 
to EPCR would be expected to be beneficial. 
It is difficult to measure the capacity for 
APC generation in patients. In the study by Liaw 
et al. the ability to activate PC was estimated in 
different patients by measuring F1+2 (a marker 
for thrombin generation) and APC levels. A low 
APC level despite elevated F1+2 levels 
suggested that the ability to activate PC is 
impaired (43). However, the plasma level of 
APC and/or F1+2 is dependent not only on the 
generation but also on clearance rates of these 
markers, which may vary in different patients. In 
addition, the half-life of thrombin in the 
circulation is very short (17) and it is important 
to keep in mind that an estimate of APC 
generation capacity based upon these markers 
applies only for endothelial cells where sufficient 
concentrations of thrombin are present in the 
microenvironment to actually support PC 
activation. It is therefore possible that WE 
infusion can support PC activation even in 
patients with elevated F1+2 levels and a low 
APC level by targeting endothelial cells that are 
not exposed to the thrombin generated 
endogenously. 
In conclusion, our finding that powerful 
autocrine barrier protective signaling is 
mechanistically linked to the endogenous PC 
activation pathway has important implications 
for novel approaches to treat systemic 
inflammation in patients. 
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FIGURE LEGENDS 
Fig 1. APC generation on the endothelial cell surface and barrier protective 
signaling. (A) APC generation. EA.hy926 cells were grown to confluency in 12-well plates 
followed by three washes with 1 ml serum free medium. The cells were incubated at 37°C in the 
presence of 80 nM PC in the absence or presence of the indicated concentrations of thrombin. 
Where indicated, the Xa inhibitor NAP5 (1 µM; open triangles) or the thrombin inhibitor hirudin 
(100 nM; open squares) were present. At the indicated time points amidolytic APC activity was 
determined in the cell medium using the chromogenic substrate S-2366 in the presence of 100 nM 
hirudin. A typical experiment of 4 is shown. (B) Barrier protective signaling. Confluent cells in a 
dual chamber system were incubated for 3 h in serum-free growth medium with the indicated 
concentrations of thrombin in the absence (gray bars) or presence (black bars) of 80 nM PC in 
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both the upper and lower chamber. Permeability was tested using Evans blue-labeled albumin 
before (open bars in each group) and after (closed bars) an additional 10 min incubation with 5 
nM thrombin. Means±SEM are shown (n=6, *p<0.05 compared to no thrombin). P-values 
comparing results in the absence and presence of PC are indicated (ns=not significant).  
 
Fig 2. PC activation and PAR1-dependent signaling by wildtype thrombin and 
thrombin W215A/E217A (WE). (A) PC activation. APC activity generated upon 90 min 
incubation of confluent EA.hy926 cells in 12-well plates with 80 nM PC and the indicated 
concentrations of either wildtype thrombin (closed circles) or WE (open circles) was determined 
using the chromogenic substrate S-2366 (means±SEM, n=2). (B) PAR1 dependent signaling. 
Erk1/2 phosphorylation compared to control was analyzed after a 5 min incubation with the 
indicated concentrations of either wildtype thrombin (closed circles) or WE (open circles) 
(means±SEM, n=3). (C) Confluent cells in the dual chamber system were incubated for 3 h with 
the indicated concentrations of WE in the upper chamber. Permeability was tested before (open 
bars) and after an additional 10 min incubation with 5 nM thrombin (closed bars) (means±SEM, 
n=4). 
 
Fig 3. Barrier protective signaling in response to WE in the presence of PC versus 
exogenous APC. Confluent EA.hy926 cells were incubated for 3 h with either the indicated 
concentrations of WE + 80 nM PC or exogenous APC in the upper chamber. (A,B) Permeability 
was tested before (open bars) and after (closed bars) an additional 10-min incubation with 5 nM 
thrombin. (C) APC activity in the upper chamber after the 3 h incubation in the presence of WE + 
80 nM PC (left panel) or APC (right panel) was determined using the chromogenic substrate 
Spectrozyme PCa. Of note, this substrate is hydrolyzed by APC slightly less efficiently than the 
S-2366 used in Fig. 1 and 2. Results are plotted with linear regression lines. (D) Permeability is 
plotted as a function of APC concentration for the endogenously generated APC (open circles) 
and exogenous APC (closed circles). Means±SEM are shown (n=6, *p<0.05 compared to 
control). 
 
Fig 4. Efficient barrier protective signaling in response to endogenous APC 
generation on HAECs. Confluent human aortic endothelial cells (HAECs) were incubated for 3 
h with WE in the absence and presence of PC or with exogenous APC as indicated. Permeability 
was tested before (open bars) and after (closed bars) an additional 10-min incubation with 5 nM 
thrombin. APC activity in the upper chamber after the 3 h incubation was determined using the 
chromogenic substrate Spectrozyme PCa. Means±SEM are shown (n=6, *p<0.05 compared to 
control). 
 
Fig 5. Effects of recombinant wildtype APC and APC S360A on endothelial barrier 
integrity. Subconfluent (upper panels) or confluent (lower panels) EA.hy926 cells were 
incubated for 3 h with the indicated agonists in both the upper and lower chambers at either 4 nM 
(left panels) or 16 nM (right panels) followed by determination of permeability. Permeability of 
confluent cells was tested before (open bars) and after (closed bars) an additional 10-min 
incubation with 5 nM thrombin. Shown are means±SEM (n=8, *p<0.05 compared to control). 
 
Fig 6. Mechanistic coupling of PC activation and barrier protective signaling by 
APC. Confluent EA.hy926 cells were incubated with control or 80 nM recombinant wildtype PC 
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 11
or PC S360A in the upper chamber as indicated. In each group 4 nM WE and 3.3 nM APC were 
also present either alone or in combination. After 3 h, APC activity in the upper chamber was 
determined using the chromogenic substrate Spectrozyme PCa and permeability was tested before 
(open bars) and after (closed bars) an additional 10 min incubation with 5 nM thrombin. Shown 
are means±SEM (n=8, *p<0.05, **p<0.005 compared to no agonist). 
 
Fig 7. Effect of cleavage-blocking anti-PAR1 on barrier protective signaling by 
endogenously generated APC. Confluent EA.hy926 cells were incubated for 3 h with the 
indicated agonists in the upper chamber in the absence (left panel) or presence (right panel) of 
cleavage blocking anti-PAR1. PAR2 can induce barrier protective effects (23) and the PAR2 
agonist peptide SLIGRL was used as a control. APC activity in the upper chamber was tested at 
the end of the 3 h incubation period using the chromogenic substrate Spectrozyme PCa. 
Permeability relative to no agonist control after an additional 10 min incubation with 20 µM 
PAR1 agonist peptide is shown (means±SEM, n=8, *p<0.05, **p<0.005 compared to no agonist).  
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